It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

1 **Rapid Biphasic Decay of Intact and Defective HIV DNA** 2 **Reservoir During Acute Treated HIV Disease**

3

4 Alton Barbehenn¹, Lei Shi², Junzhe Shao², Rebecca Hoh¹, Heather M. Hartig¹, Vivian Pae¹, 5 Sannidhi Sarvadhavabhatla¹, Sophia Donaire¹, Caroline Sheikhzadeh¹, Jeffrey Milush⁵, Gregory 6 M. Laird³, Mignot Mathias³, Kristen Ritter³, Michael Peluso¹, Jeffrey Martin⁴, Frederick Hecht¹, 7 Christopher Pilcher¹, Stephanie E. Cohen^{1,6}, Susan Buchbinder⁶, Diane Havlir¹, Monica 8 Gandhi¹, Timothy J. Henrich⁵, Hiroyu Hatano¹, Jingshen Wang², Steven G. Deeks¹, and Sulggi 9 A. Lee $*^1$

10

11 ¹Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of 12 California San Francisco, San Francisco, CA 94110, USA. ² Department of Biostatistics, 13 University of California Berkeley, Berkeley, CA 94110, USA. ³ Accelevir Diagnostics, Baltimore, 14 MD 21202, USA. ⁴Department of Biostatistics & Epidemiology, University of California San 15 Francisco, CA 94158, USA. ⁵ Department of Medicine, Division of Experimental Medicine, 16 University of California San Francisco, San Francisco, CA 94110, USA. ⁶ San Francisco 17 Department of Public Health, San Francisco, CA 94102, USA.

18

19 [#]Co-Lead Authors: Alton Barbehenn and Lei Shi

20 Corresponding Author: sulggi.lee@ucsf.edu

21 **ABSTRACT**

22 Antiretroviral therapy (ART) is not a cure. Upon ART cessation, virus rapidly rebounds from 23 latently-infected cells ("the HIV reservoir"). The reservoir is largely stabilized at the time of ART 24 initiation and then decays slowly. Here, leveraging >500 longitudinal samples from 67 people 25 with HIV (PWH) treated during acute infection, we developed a novel mathematical model to 26 predict reservoir decay using the intact proviral DNA assay (IPDA) from peripheral CD4+ T cells. 27 Nonlinear generalized additive models adjusted for initial CD4+ T count, pre-ART viral load, and 28 timing of ART initiation demonstrated rapid biphasic decay of intact DNA (week 0-5: $t_{1/2} \sim 0.71$) 29 months; week 5-24: $t_{1/2}$ ~3.9 months) that extended out to 1 year of ART, with similar trends for 30 defective DNA. Predicted reservoir decay were faster for participants individuals with earlier 31 timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. These 32 estimates are ~5-fold faster than prior reservoir decay estimates among chronic-treated PWH. 33 Thus, these data add to our limited understanding of host viral control at the earliest stages of 34 HIV reservoir stabilization, potentially informing future HIV cure efforts aimed at diverse, global 35 population of PWH initiating ART at varying stages of disease.

36

37 Abstract Word Count (approx. 150): 198

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

39 **Title Word Count** (max 15): 15

40 **Manuscript Word Count** (5000; Methods 3,000 words): 4,122

41 **Keywords**: acute HIV; antiretroviral therapy (ART); HIV reservoir decay; pre-exposure 42 prophylaxis (PrEP)

43 **CONFLICTS:** The authors do not have a commercial or other association that might pose a 44 conflict of interest.

45 **FUNDING:** This work was supported in part by the National Institutes of Health: K23GM112526 46 (SAL), the DARE Collaboratory (UM1AI164560; SGD), the AccelevirDx HIV Reservoir Testing 47 Resource (U24AI143502; GML), and NIH/NIAID R01A141003 (TJH). This work was also 48 supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50- 49 RGRL; SGD), the Bill & Melinda Gates Foundation (INV-002703; SGD), and investigator-50 initiated research grants from ViiV Healthcare (A126326; SAL) and Gilead Sciences (IN-US-51 236-1354; SAL). The content of this publication does not necessarily reflect the views or policies 52 of the Department of Health and Human Services, the San Francisco Department of Health, nor 53 does mention of trade names, commercial products, or organizations imply endorsement by the 54 U.S. Government. The funders had no role in study design, data collection and analysis, 55 decision to publish, or preparation of the manuscript.

56 **Previous presentation:** Preliminary data were presented in July 2023, as a poster presentation 57 at the International AIDS Society (IAS) conference in Brisbane, Australia.

58 **Reprints:** Reprint requests can be directed to Dr. Sulggi Lee, the corresponding author (contact 59 information above).

60 **Acknowledgements:**

61 The authors wish to acknowledge the participation of all the study participants who contributed 62 to this work as well as the clinical research staff of the UCSF Treat Acute HIV and SCOPE

63 cohorts who made this research possible. All funders had no role in study design, data 64 collection and analysis, decision to publish, or preparation of the manuscript. All authors 65 provided critical feedback in finalizing the report. HH, SGD, and SAL conceived and designed 66 the study. HH, SGD, and SAL obtained funding to support the clinical enrollment of study 67 participants, and SAL and SGD obtained funding to support characterization of the HIV 68 reservoir. SEC, SB, DH, and MG facilitated coordination with San Francisco Department of 69 Public Health and Ward 86 clinical services to link patients into care and provided critical 70 feedback on the clinical management of acute HIV. SAL, RH, SGD, TJH, HMH, SS, SD, and VP 71 coordinated the collection, management, and quality control processes for the clinical data, and 72 SAL, SGD, JM, FH, and CP provided biospecimens. JM and TJH performed biospecimen 73 processing, GML, MM, and KR performed the HIV reservoir assays. LS developed the initial 74 decay models, under the guidance of SAL and JW, and AB and SAL further modified these 75 models under the guidance of JW, LS, and JS. GML, MM, KR, LS, JS, JW, and SAL analyzed 76 the HIV reservoir data. SAL, AB, LS, and JW wrote the report. SS, SD, VP, CS, LS, JS, JW, and 77 SAL finalized data visualization for the manuscript. All authors provided critical feedback in 78 finalizing the manuscript.

79 **INTRODUCTION**

80 Despite over four decades of research, we do not yet have an HIV cure. While 81 antiretroviral therapy (ART) is able to suppress virus to undetectable levels, virus rapidly 82 rebounds from latently-infected cells ("the HIV reservoir") within weeks of ART interruption.¹⁻⁸ 83 Thus, a major goal is to eradicate and/or accelerate the decay of the reservoir in order to 84 achieve clinical remission. However, HIV cure trials to date have largely failed to demonstrate a 85 clinically meaningful reduction in the size of the HIV reservoir and/or lead to sustained ART-free 86 Tremission.⁹⁻¹² The majority of these trials have been conducted among people with HIV (PWH) 87 treated during chronic infection and were administered therapeutic interventions long after the 88 reservoir was established (i.e., several years after initiating ART)¹³⁻¹⁸. Recent combination 89 therapy trials (e.g., broadly neutralizing antibodies given with ART) have yielded more promising 90 results, and a few participants have demonstrated evidence of extended ART-free viral control¹⁹⁻ 21 21 , but the mechanisms by which these small number of participants exhibit enhanced viral 92 control remain unclear.

93 One possibility is that since PWH treated during chronic HIV often have larger 94 reservoirs²²⁻²⁹ and exhausted/dysfunctional immune responses³⁰⁻³² (due to prolonged periods of 95 untreated HIV infection), that demonstrating measurable HIV remission from these small trials 96 may have been more challenging. Indeed, individuals who initiate ART "earlier" (within 6 months 97 after infection) may be more likely to become "post-treatment controllers" (PTCs), rare PWH 98 who, for unclear reasons, are able to control virus without ART following a brief of initial ART 99 suppression.³³ Thus, different host factors, such as timing of ART initiation in relation to 100 chronicity of HIV infection, initial CD4+ T cell count, or pre-ART HIV viral load, may have 101 profound impact on estimating HIV reservoir decay rates, and yet there are limited data 102 modeling decay rates while accounting for these factors. Such information would be immensely 103 useful in future HIV cure trials to compare expected reservoir decay rates in comparison to

104 curative interventions and allow generalizability of findings to a more global population of PWH 105 (treated during acute or chronic infection).

106 While there have now been a handful of studies modeling how quickly the HIV reservoir 107 decays during prolonged ART (studies spanning nearly 20 years on ART)³⁴⁻³⁷, there have been 108 no studies modeling HIV reservoir decay rates after acute treated HIV infection. Here, 109 leveraging ~500 longitudinal blood measurements of the HIV reservoir, we developed a novel 110 mathematical model of reservoir decay among 67 participants from the UCSF Treat Acute HIV 111 cohort initiating ART within 100 days of the estimated date of HIV infection.³⁸ These data 112 demonstrate for the first time that the reservoir decays significantly faster in acute compared to 113 chronic treated PWH initiating ART. 3 Our partially parameterized mathematical model flexibly 114 estimated the rate of change of the HIV reservoir to include participant-level random effects (to 115 account for heterogeneity in decay rates) as well as key clinical covariates (initial CD4+ T count, 116 pre-ART viral load, and days since estimated date of HIV infection).

117 We fit various mono-, bi-, and triphasic decay curves for both HIV "intact" (infected cells 118 harboring intact viral sequences able to produce infectious virions) and "defective" (the majority 119 of the HIV reservoir but incapable of producing infectious virions) DNA. For both intact and 120 defective DNA, we observed clear biphasic decay patterns with an initial rapid first phase of 121 decay (which was nearly identical to previous estimates in chronic treated PWH initiating ART 3) 122 followed by a second slower phase of decay (~5-fold faster that previously reported in chronic 123 PWH initiating ART). Furthermore, these decay rates were significantly faster among individuals 124 with known clinical factors associated with enhanced host viral control: higher initial CD4+ T cell 125 count, earlier initiation of ART, and lower pre-ART viral loads. $22,23,34,39,40$ These data are the first 126 to our knowledge to describe a predictive mathematical model to describe HIV reservoir decay 127 rates during acute treated HIV.

128

129 **RESULTS**

130 **Characteristics of study participants**

131 A total of 67 adults (83% of those screened) with a new diagnosis of acute HIV (<100 132 days between the estimated date of detected HIV infection to the baseline study visit/ART 133 initiation) were included in the UCSF Treat Acute HIV cohort (**Table 1, Supplementary Figure 1**) ⁴¹ 134 . All 67 participants completed follow-up in the study for the full 24 weeks. A large 135 proportion (65.7%) of participants co-enrolled in our longitudinal UCSF SCOPE HIV cohort and 136 remained in study for additional follow-up, with study visits approximately every 3-4 months 137 thereafter. Follow-up for the current analysis included longitudinal sampling for a median of 0.81 138 years. The estimated dates of detected infection (EDDI) were calculated to determine recency 139 of infection using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/) 42 140 (**Supplementary Figure 2**). These estimates were then used to estimate acute HIV Fiebig 141 stages ⁴³⁴⁴. Consistent with our San Francisco-based study population, participants were mostly 142 male (97%) and reflected local and national racial/ethnic trends of higher incident acute HIV in 143 these populations⁴⁵. Baseline study visit HIV-1 antigen/antibody (Architect) and HIV-1 antibody 144 (Geenius) testing demonstrated 27% and 28% false negative/indeterminate rates, respectively, 145 consistent with our San Francisco Department of Public Health (SFDPH) reported estimates for 146 new acute HIV diagnoses ⁴⁶ (Supplementary Figure 4). Genotype data (Monogram) were 147 available for a subset of 57 participants; 77% had wild-type HIV, 9% had M184V/I mutations (all 148 were reported among participants citing prior and/or current PrEP use), and 14% had evidence 149 of possible partner-transmitted resistance mutations (based on referral of newly diagnosed 150 partners within our cohort and/or SFDPH partner tracing 46).

151 Our cohort also reflected a high proportion of self-reported prior PrEP use (42% 152 reporting ever use while 20% reported PrEP use in the past 10 days), reflecting San Francisco's 153 early and widespread adoption of PrEP⁴⁶. All PrEP reported in this study was oral PrEP with 154 tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), as this was the only form clinically 155 available during the study period. Among individuals reporting overlapping PrEP use within 10

156 days from their estimated date of HIV acquisition (using self-reported PrEP use and the infection 157 dating tool as described in the Methods 42), six participants were deemed to have probable HIV 158 acquisition while on PrEP (median baseline plasma log_{10} HIV RNA = 2.2 copies/mL), which was 159 approximately ~3 log₁₀ lower than those not reporting PrEP overlap (Table 1). One participant 160 was estimated to have acquired HIV in the setting of therapeutic PrEP concentrations 161 (confirmed by plasma and hair ART concentrations), as described in our previous publication 47 .

162

163 **Rapid biphasic decay of intact and defective DNA**

164 We estimated the rate of change of HIV intact and defective DNA as log_{10} copies per 10⁶ 165 peripheral CD4+ T cells (quantified using the IPDA), as well as the influence of clinical 166 covariates on the rate of HIV DNA change. A median of 2×10^6 CD4+ T cells per sample 167 (median viability of 97%) was recovered from peripheral CD4+ T cells isolated by negative 168 immunomagnetic selection. Duration of ART was used as the primary predictor to allow for time-169 varying estimation of changes within each person across the sampling timepoints. The rate of 170 change was estimated for the primary outcome of HIV intact DNA, as well as the secondary 171 outcome of defective DNA (3' defective, 5' defective, and total combined defective provirus). We 172 initially modeled HIV intact and defective DNA using a linear effect of time on ART (which 173 assumes a constant rate of change regardless of the duration of viral suppression). However, 174 we observed evidence of nonlinearity, and thus, instead of fitting a single constant rate of 175 decline, we fit nonlinear generalized additive models to estimate the appropriate nonparametric 176 relationship for each predictor term.

177 Clinical covariates of age, gender, pre-ART CD4+ T cell count, pre-ART viral load, and 178 timing of ART initiation (number of weeks since estimated date of infection) were tested for 179 inclusion in these models. Final models included terms for initial CD4+ T cell count, pre-ART 180 viral load, and timing of ART initiation. **Figure 4** illustrates that of the three clinical covariates, 181 only timing of ART initiation changes the shape of the reservoir decay, whereas initial CD4+ T

182 cell count and pre-ART viral load account for patient-level variation. Additionally, we added 183 individual participant-level random effects into regression models to account for heterogeneity in 184 outcome measures within individuals (see **Statistical Methods**). Given the small number of 185 participants reporting PrEP use within 10 days of HIV acquisition (**Table 1**), inclusion of this 186 parameter as a covariate in the model and sensitivity analyses excluding these individuals did 187 not change results, and thus was not included as a covariate in final models. In addition, 188 participants reporting potential PrEP overlap did not clearly fall in the lower range of reservoir 189 measurements, but rather, were dispersed among the range of HIV intact and defective DNA 190 values (**Supplementary Figure 5**).

191 Therefore, we then fit various mono-, bi-, and triphasic decay curves for both HIV intact 192 and defective DNA using semiparametric generalized additive models that introduced up to two 193 inflection points, tau (τ), delineating distinct exponential decay phases (see **Statistical** 194 **Methods**). We then estimated the decay model's inflection points τ by minimizing prediction 195 errors as measured by leave-one-out mean absolute deviation (MAD) and leave-one-out mean 196 squared error (MSE) approaches (**Figure 2, Supplementary Figure 7**). For HIV intact DNA, we 197 found that the biphasic model best fit our data, while for defective DNA, the biphasic and 198 triphasic models were relatively equivalent in performance (**Supplementary Figure 6**). A 199 biphasic model outperformed a monophasic decay model for both intact and defective DNA. 200 These analyses demonstrated that $\tau = 5$ weeks closely fit our data using this biphasic model. To 201 ensure that the selected $\tau = 5$ was not influenced by potential outlier data, we performed three 202 different sensitivity analyses excluding (1) individuals reporting prior PrEP use within 10 days of 203 estimated date of HIV infection, (2) participants with plasma viral load "blips" (defined as a one-204 time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL between weeks 205 0-24), and (3) participants with sudden increases in HIV intact DNA (defined as >50% increase 206 between two consecutive measurements of HIV intact DNA during weeks 0-24). These

207 sensitivity analyses demonstrated that $\tau = 5$ is a reasonable choice for the mode l's inflection 208 point and that the model estimates were unchanged after excluding these potential outliers.

209 Based on our final selected multivariate model, we observed a rapid biphasic decay of 210 both intact and defective DNA during acute treated HIV infection, with an initial steep decay until 211 approximately 5 weeks of ART, followed by a slower decay (**Figure 1a**). For example, for HIV 212 intact DNA, we estimated that the first phase of reservoir decay had an estimated half-life $(t_{1/2})$ 213 \sim 0.70 (95% confidence interval [CI] = 0.59, 0.82) months in unadjusted models and a t_{1/2} \sim 0.71 214 (95%CI = 0.60, 0.82) months in models adjusted for clinical covariates. This was followed by a 215 slower second decay phase after ~5 weeks of ART with a $t_{1/2}$ ~3.61 (95%CI = 2.81, 4.42) 216 months in unadjusted models and a $t_{1/2}$ ~3.86 (95%CI = 2.99, 4.72) months in models adjusted 217 for clinical covariates. Similar first phase (weeks 0-5) decay rates were observed for HIV 218 defective DNA in unadjusted ($t_{1/2}$ ~0.34, 95% CI = 0.29, 0.38) and adjusted ($t_{1/2}$ ~0.34, 95% CI = 219 0.29, 0.39) models but estimates were less stable for the second phase of defective DNA decay 220 due to considerable variability in these data (**Figure 1, Supplementary Tables 1-2**). Thus, we 221 did not observe discernable differences in decay rates for HIV intact versus defective DNA in 222 the first five weeks after ART initiation, in contrast to prior reservoir decay studies among 223 chronic treated PWH during nearly 20 years of $ART^{34-36,48}$, although we did see a discernable 224 differences in decay rates for HIV intact versus defective DNA from weeks 5-24 that seems to 225 continue out to a year (**Supplementary Figure 7**).

226 For all models, fitted values closely predicted observed values for both intact and 227 defective DNA (**Supplementary Figure 10**). We further validated our models using our clinical 228 data to determine whether our model captured expected clinical relationships. Our model tells 229 us that for every additional week ART initiation is delayed, the half-life for the first phase of HIV 230 intact reservoir decay increases by ~0.02 months; similarly, the defective reservoir's half-life 231 increases by ~0.01 months. Importantly, our model tells us that the timing of ART initiation has a 232 larger impact on the second phase of HIV reservoir decay. During weeks 5-24, our model

233 predicts an increase in intact reservoir decay half-life of ~0.27 months for every week delay in 234 ART initiation and no significant change to the defective HIV reservoir (**Supplementary Table** 235 **3**). Concretely, this means that a patient who initiates ART 30 days post infection has an 236 average intact HIV reservoir decay half-life of ~2.5 months while a patient who initiates ART 100 237 days post infection has an average intact HIV reservoir decay half-life of ~6.3 months; as 238 suggested in **Supplementary Figure 7**, this may continue out to a year on ART. Clinical 239 validation of the initial CD4+ T cell count and pre-ART viral load terms is more straightforward 240 because they are only used to account for participant-level variation, not changes in half-life. 241 Our model tells us that both lower pre-ART viral load and higher initial CD4+ T counts were 242 associated with lower intact and defective HIV DNA reservoirs (**Supplementary Table 4**). 243 Finally, using bootstrapping methods (random sampling of the clinical covariates to compute 244 model predictions for 300 new participants) we estimated HIV DNA intact and defective counts 245 and then averaged the model predictions within strata (tertiles) of each clinical parameter (e.g., 246 average HIV intact DNA decay rate for the first, second, and third tertiles of pre-ART viral loads 247 (**Figure 5**). These analyses clearly demonstrated that our model predicts lower HIV intact and 248 defective DNA reservoirs for individuals with higher initial CD4+ T cell count and lower pre-ART 249 viral load, and the HIV intact and defective DNA reservoirs decayed more rapidly for earlier 250 timing of ART initiation.

251

252 **DISCUSSION**

253 The HIV reservoir is established within days after initial viral infection⁴⁹⁻⁵¹, and although 254 ART can suppress virus to undetectable levels in the blood, persistently cells are a source of 255 viral rebound when therapy is interrupted. A major goal of HIV cure strategies is to induce ART-256 free remission⁵². Thus, clearly defining complex reservoir decay dynamics at the time of HIV 257 reservoir establishment – including how key host factors such as the timing of ART initiation, 258 initial CD4+ T cell count, and pre-ART viral load influence these decay rates – will be important

259 in interpreting HIV cure trial results. Potential promising therapeutic interventions may be 260 optimally studied in specific patient populations, but results from such studies can still inform 261 future therapies for all PWH. For example, chronic treated PWH may benefit from the same 262 curative interventions as acute treated PWH but might require adjunctive therapies to reverse 263 cell exhaustion⁵³⁻⁵⁵. Here, using a unique cohort of individuals followed longitudinally since acute 264 HIV infection and immediate ART initiation, we observed a clear biphasic decay of the reservoir 265 during the first year of therapy. Decay rates were accelerated among individuals with clinical 266 factors associated with enhanced viral control (higher initial CD4+ T cell count, lower pre-ART 267 viral load, and earlier timing of ART initiation)^{22,23,34,39,40} and were faster than prior reports among 268 chronic treated PWH initiating ART^3 .

269 Our model allowed flexible estimation of HIV intact and defective decay rates while 270 adjusting for clinical covariates, in contrast prior studies which mostly fit fully parameterized, 271 mixed effects models^{3,48,56,57}. For example, with HIV intact DNA, the observed initial rapid phase 272 was estimated to have a half-life $(t_{1/2})$ of 0.71 months until approximately 5 weeks of ART. This 273 was then followed by a slower second phase of decay with a half-life of 3.86 months. Strikingly, 274 our estimated decay rate of HIV intact DNA during the first phase of decay is nearly identical to 275 estimates of HIV intact DNA among chronic treated PWH initiating ART in a prior study ($t_{1/2}$ = 276 0.43 months)³. However, our estimates for the second phase of decay ($t_{1/2}$ = 3.9 months) were 277 ~5-fold faster than reported their study of chronic treated PWH, where the second phase of 278 decay was estimated to be much longer ($t_{1/2}$ = 19 months)³. This initial rapid decay phase is 279 thought to reflect death of productively infected cells in the setting of rapid antigen reduction 280 with ART initiation⁴ and thus similarly rapid decay rates immediately after ART initiation may be 281 similar for PWH who start therapy during acute, as well as chronic infection. Meanwhile, the 282 second phase of decay is thought to reflect a "contraction phase" when activated cells shift to a 283 more memory phenotype⁵⁸ and therefore, the larger differences that we observed in our cohort

284 compared to earlier findings in chronic-treated PWH may indicate a unique phase during which 285 intervention may considerably influence HIV reservoir decay rates with earlier ART initiation.

286 PWH treated during acute infection have been shown to have less exhausted/relatively 287 intact host immune responses due to earlier removal of antigen and reduction of subsequent 288 inflammation and immune activation. 59 For these reasons, the study of acute treated PWH 289 provides a unique opportunity to identify the optimal timing, potential "windows of time" during 290 which intervention with immunomodulatory agents may have a greater impact on reducing the 291 reservoir size. Most (but not all) studies have shown that those who initiate ART during acute 292 and early infection also have smaller reservoirs than PWH who initiated ART during chronic 293 infection $22-26,28,50,51,60$. Given the limited data demonstrating reservoir decay rates during acute 294 and early infection $26,50,61,62$, none of which included statistical modeling incorporating key clinical 295 parameters such as timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load, 296 our data add considerable insight to our current understanding of the timing and modification of 297 early HIV reservoir establishment and stabilization. Nonetheless, there are a wealth of other 298 invaluable HIV cohorts, such as the RV254/SEARCH 010 study, that if these data are compiled 299 across studies, may further inform our understanding of how quickly the reservoir decays, and 300 how factors such as ART initiation during acute infection may alter those trajectories. Indeed, in 301 the RV254/SEARCH 010 study, the presented HIV reservoir data (their study measured 302 integrated and unintegrated HIV DNA) plotted longitudinally, seem to indicate that similar decay 303 patterns might be observed in their cohort as well. 50 Acute treated PWH in the study 304 demonstrated rapid decay of both integrated and unintegrated HIV DNA while among chronic 305 treated PWH in their study, only a modest decline in integrated HIV DNA was observed. (The 306 latter may be an artifact of the previously noted observation that among chronic PWH, the 307 majority of integrated HIV DNA tend to be latent or defective, rather than productively infected, 308 $$ as in acute PWH). 50

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint
(**which was not certified by peer review)** is the author/funder, who has granted

309 While there have been limited studies describing HIV reservoir decay rates in acute 310 treated PWH, there now been several studies describing HIV reservoir decay rates during 311 chronic treated HIV (followed as long as \sim 20 years of ART). These studies have now 312 demonstrated that cells harboring "intact" provirus (i.e., infected cells capable of producing 313 infectious virus) decay more quickly than defective provirus (infected cells that make up the 314 majority of the reservoir and contain deletions and/or mutated viral sequences^{63,64}) during long-315 term ART $34-37$. While our data are unable to yet describe decay rates past 1 year of ART, our 316 study offers for the first time a detailed estimation of HIV reservoir decay rates in the first few 317 weeks to months of ART initiation during acute HIV. While we did not observe discernable 318 differences between HIV intact and defective decay rates as previously described among 319 chronic PWH, $34-36,48$ we did find that HIV defective DNA was much more "noisy" than intact DNA 320 (as shown in **Figure 2**), and thus the lack of statistical significance in the second phase of decay 321 reported here may be further investigated in future larger studies. Indeed, the putative 322 mechanism underlying the differential decay rates of HIV intact and defective reservoir during 323 long-term ART is thought to be due to selective immune clearance over time; cells harboring 324 inducible "replication-competent" virus may be more readily detected by host immune surveillance and cleared.^{34-36,48,65,66} It is unclear if these same factors are at play as early as 5 326 weeks after initiating ART during acute HIV infection.

327 Studies estimating HIV reservoir decay rates in chronic PWH have shown that the HIV 328 intact reservoir decays with a t_{1/2} of ~44 months. $67,68$ Subsequent studies studying individuals as 329 far out as \sim 20 years of ART suggest that this $t_{1/2}$ further slows to \sim 224-276 months after about 330 7 years of ART. $34-36,48$ Interestingly, these long-term follow-up studies have found that during this 331 late phase of reservoir decay, some individuals appear to demonstrate a plateau, or even a 332 slight increase, in their HIV intact reservoir size. The reasons for this are unclear but some have 333 argued that this may be due to a "tipping point" at which the host immune response has cleared

334 the majority of the intact reservoir in the body and is then counterbalanced by ongoing cell 335 proliferation. 48

336 While we were able to perform an in-depth statistical modeling study, leveraging unique 337 acute treated participant samples and a large number of longitudinal HIV reservoir 338 measurements, our study has several limitations that deserve mention. While the peripheral 339 HIV reservoir largely reflect infected-cell populations originating from tissues reservoir, ^{49,50,69,70} 340 we only included peripheral CD4+ T cell HIV reservoir measures in our model. In addition, while 341 we used the widely utilized IPDA (a high throughput assay that can be performed on this large 342 number of samples), alternative assays, such as near-full length proviral sequencing or QVOA, 343 would have been informative to further interpret our findings (if these were able to be performed 344 at the scale required for this large number of samples). However, HIV intact DNA measured 345 using the IPDA has been shown to closely reflect trends resulting from these other assays, 346 even considering the known enrichment of integrated forms of HIV DNA observed in acute 347 PWH.⁵⁰ As with all molecular assays for HIV, certain polymorphisms at primer or probe binding 348 sites can impact IPDA assay performance. In this study, we observed IPDA signal failure for 6 349 of 67 participants (8.9%) – a rate consistent recent reports on very large cohorts of PWH from 350 North America and Europe where subtype B predominates (6-7%) $34,71$. While the IPDA does not 351 perfectly discriminate intact from defective proviruses, the cross sectional and longitudinal 352 correlations between IPDA and QVOA measurements of the HIV reservoir strongly support the 353 use of the higher throughput IPDA in large scale studies of proviral decay dynamics. We did not 354 include parameters for potential influences from changes in clonal landscape over time as our 355 study did not include HIV integration analyses. However, the clonal landscape at the time of 356 acute HIV is extremely diverse, and we hypothesize that this effect is more likely to have higher 357 impact after longer duration of ART suppression. Future models should include these 358 parameters to formally test this hypothesis. Finally, there are few highly characterized acute HIV 359 cohorts to date, and each study possesses unique host and viral characteristics making direct

360 cross-cohort comparisons challenging. These cohort-specific factors include host genetics, 361 socio-behavioral demographics (our study included mostly men who have sex with men), clinical 362 practices and public policy guidelines for ART initiation, and viral subtype (mostly subtype B in 363 our study). Our HIV reservoir decay model should be further validated in these global 364 populations, including individuals initiating treatment during chronic HIV, which represents the 365 majority of people currently living with HIV. Overall, these data encourage future collaborative 366 work to determine decay dynamics across global populations so that future cure strategies may 367 be effective across clades and in people with larger reservoirs, exhausted immune responses 368 who initiated ART during chronic HIV.

369

370 **METHODS**

371 **Study participants**

372 Individuals with newly diagnosed acute HIV (<100 days from estimated date of infection) 373 were enrolled in the UCSF Treat Acute HIV cohort between December 1, 2015 to November 30, 374 2020 and co-enrolled in the UCSF SCOPE HIV cohort, an ongoing longitudinal study of over 375 2,500 PWH to characterize the natural history of HIV disease. Eligible participants were 376 consented, provided same-day ART initiation with tenofovir/emtricitabine (TDF/FTC, then 377 TAF/FTC once available in 2016) + dolutegravir (DTG) and linked to clinical care 46 . Individuals 378 reporting concomitant PrEP use (<100 days from any potential exposure to HIV by history 379 and/or clinical test results) were also started on darunavir+ritonavir (DRV/r) as a fourth drug, 380 which was continued until confirmation of baseline HIV genotyping test results (Monogram 381 Biosciences, South San Francisco, CA, U.S.A.). Additional ART changes necessary for clinical 382 care (e.g., laboratory abnormalities, drug-drug interactions, and/or participant preference) were 383 honored and adjusted during the period of study. Participants signed a release of information

384 which allowed clinical data extraction to determine prior HIV negative test results from the 385 SFDPH, as well as additional HIV test results.

386 Study participants were seen for monthly study visits for the first 24 weeks and then 387 every 3-4 months thereafter. Inclusion criteria for the study were prior HIV negative testing 388 within the last 90 days, laboratory-confirmed HIV-1 infection by antibody/antigen and/or plasma 389 HIV RNA assay, and willingness to be participate in the study for at least 24 weeks. Participants 390 with severe renal or hepatic impairment, concurrent treatment with immunomodulatory drugs, or 391 exposure to any immunomodulatory drugs in the preceding 90 days prior to study entry, 392 pregnant or breastfeeding women, or participants unwilling to agree to the use a double-barrier 393 method of contraception throughout the study period, were excluded. For each study participant, 394 using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/)⁴², the estimated date 395 of detected HIV infection (EDDI), along with a "confidence interval" for early probable (EP-EDDI) 396 and late probable (LP-EDDI) date was calculated using each participant's prior clinical HIV test 397 results, as well the study baseline HIV test results. At each visit, detailed interviews included 398 questions regarding current medications, medication adherence, intercurrent illnesses, and 399 hospitalizations were performed. In addition, peripheral blood sampling at each visit was 400 performed to measure plasma HIV RNA, CD4+ T cell count, and clinical labs (complete blood 401 count, metabolic panel), as well as blood for storage - PBMCs and plasma. For a subset of 402 individuals who reported potential PrEP overlap with HIV EDDI, participants were consented 403 and co-enrolled in the SeroPrEP study and dried blood spot and hair were collected to confirm 404 PrEP use. Finally, some individuals were invited to participate in optional sub-studies, which 405 included leukapheresis and lymphoid tissue sampling (rectal and ileal biopsies, lymph node fine 406 needle aspirate) after 12 months of ART suppression (data not included here in this paper). All 407 participants provided written informed consent, and the institutional review board of UCSF 408 approved the research.

409

410 **HIV reservoir quantification**

411 There is currently no "gold standard" for measuring the HIV reservoir. Moreover, the HIV 412 reservoir largely consists of "defective" virus that harbors mutations prohibiting the production of 413 infectious virus $63,64$. The frequencies of HIV intact and defective (3' and 5') DNA were quantified 414 using the intact proviral DNA assay (PDA), as previously described 72 . Briefly, CD4+ T cells 415 were isolated from cryopreserved PBMCs (EasySep Human CD4+ T cell Enrichment Kit, 416 Stemcell Technologies), with cell count, viability, and purity assessed by flow cytometry both 417 before and after selection. Negatively selected CD4+ T cells were recovered for the samples, 418 and genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen). DNA concentration 419 and quality were determined by fluorometry (Qubit dsDNA BR Assay Kit, Thermo Fisher 420 Scientific) and ultraviolet-visible (UV/VIS) spectrophotometry (QIAxpert, Qiagen). The frequency 421 of "intact" HIV provirus (i.e., estimating the potentially replication-competent reservoir) was 422 determined using two multiplex digital droplet polymerase chain reaction (ddPCR) assays 423 performed in parallel: (1) the HIV-1 Proviral Discrimination reaction which distinguishes intact 424 from defective provirus via two strategically placed amplicons in HIV psi and RRE regions as 425 well as a hypermutation discrimination probe, and (2) the Copy Reference/Shearing reaction, 426 which quantifies DNA shearing and input diploid cell equivalents using the human *RPP30* gene 427 $^{\frac{72}{}}$. All ddPCR reactions were assembled via automated liquid handles to maximize 428 reproducibility and analyzed using the BioRad QX200 AutoDG Digital Droplet PCR system 429 (BioRad). Up to 700 ng of genomic DNA were analyzed per reaction, and final input DNA 430 concentrations were dependent upon the concentration of recovered DNA. Samples were batch 431 processed and analyzed, including negative controls from uninfected donors and J-Lat full-432 length clone 6.3 (E. Verdin, Gladstone Institutes and UCSF, San Francisco, CA, USA) cells as 433 positive controls, as previously described. Across the >500 IPDA measurements performed, we

434 interrogated a median of 4.8 x 10^5 CD4+ T cell genomes per assay and observed a median 435 DNA shearing index (DSI) of 0.40.

436

437 **Statistical Methods**

438 We developed a novel semiparametric biphasic decay model to estimate the rate of

439 change of HIV DNA over time in log_{10} copies per 10 6 CD4+ T cells:

 $\frac{1}{2}$

(1), I_{it} represents either the intact or defective HIV DNA counts,
at *t*-th visit. The number of weeks since ART initiation is denoted T_{it} . In equation (1), I_{it} represents either the intact or defective HIV DNA counts, of the *i*-th
441 participant at *t*-th visit. The number of weeks since ART initiation is denoted T_{it} . The model
442 additionally contr 441 participant at t-th visit. The number of weeks since ART initiation is denoted T_{it} . The model additionally controls for baseline clinical information defined as the initial CD4+ T cell count, C_i , additionally controls for baseline clinical information defined as the initial CD4+ T cell count, C_i ,

pre-ART viral load, V_i , and the estimated time between HIV infection and ART initiation, E_i . The

delay in ART i 445 approximately 60 days in our cohort. Participant-level random effects are denoted μ_i . Building delay in ART initiation is centered to have a mean of zero for later analysis; this offset is approximately 60 days in our cohort. Participant-level random effects are denoted μ_i . Building
446 . on existing models, ^{3,48} we parameterize the decay as a continuous, linear spline with a single
447 . knot at τ : 446 on existing models, $3,48$ we parameterize the decay as a continuous, linear spline with a single All the same parameterization, we can directly interpret β_1 , β_2) = $\beta_1 \cdot \min\{T_{it}, \tau\} + \beta_2 \cdot \min\{T_{it} - \tau, 0\}$. Using this parameterization, we can directly interpret β_1 as the decay rate before τ and β_2 $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ can directly interpret $β_1$ as the decay rate before τ and $β_2$ as the decay rate after τ; we use the
same parameterization for $f_2(T_{it}; τ, β_3, β_4)$ but with different $β$ values. We use a cubic spline with
450 and rati same parameterization for $f_2(T_{it}; \tau, \beta_3, \beta_4)$ but with different β values. We use a cubic spline with
450 20 regularly spaced knots for both $f_3(C_i)$ and $f_4(V_i)$. Once τ is fixed, model fitting is performed
451 $\ddot{}$ 20 regularly spaced knots for both $f_3(C_i)$ and $f_4(V_i)$. Once τ is fixed, model fitting is performed
451 using least-squares regression. When testing our model against monophasic and triphasic
452 models, we used eith 451 using least-squares regression. When testing our model against monophasic and triphasic

models, we used either linear terms or linear splines with two knots for f_1 and f_2 respectively.
453 The estimation of the inflection point, τ , is done by minimizing the model's me
454 absolute prediction error. 453 The estimation of the inflection point, τ , is done by minimizing the model's mean 454 absolute prediction error. We fixed a grid of candidate τ values from 0 weeks to 25 weeks, by τ values from 0 weeks to 25 weeks, by estimated using leave-one-out cross-455 half-week. The mean absolute prediction error was estimated using leave-one-out cross-456 validation calculated as

$$
Error(\tau) = \sum_{i,t} \left| \log_{10}(I_{it}) - \log_{10}\left(\hat{I}_{it}^{(-i)}\right) \right|, \#(2)
$$

predicted HIV DNA counts for patient *i* at time

where I_{it}^{∞} r
Di
İl where $I_{it}^{(-)}$ denotes the predicted HIV DNA counts for patient *i* at time *t* using the model fit with
458 every patient except patient *i*. This loss metric was also used to estimate the two knots in the
459 triphasic 458 every patient except patient i . This loss metric was also used to estimate the two knots in the i. This loss metric was also used to estimate the two knots in the
mation criteria (AIC) was used to compare the fits of the mono-, bi-, 459 triphasic model. Akaike information criteria (AIC) was used to compare the fits of the mono-, bi-, 460 and triphasic models.

461 Half-life estimates and their confidence intervals are computed using the multivariate 462 delta method. During the first decay phase, we are interested in estimating the baseline half-life 463 in months and the adjustment to the half-life in months due to delay in ART initiation. The half-464 life (in months) before $τ$ is calculated as

$$
t_{\frac{1}{2}}(E_i) = -\frac{0.25 \log_{10}(2)}{\beta_1 + \beta_2 E_i} = -\frac{0.25 \log_{10}(2)}{\beta_1} + \frac{0.25 \log_{10}(2) \beta_2 E_i}{\beta_1^2} + O(E_i^2), \#(3)
$$

 $\frac{1}{2}$
 $\frac{1}{2}$ $(E_i) = -\frac{\sum_{i=0}^{n} \sum_{j=0}^{n} (E_i)}{\beta_1 + \beta_2 E_i}$
second equality is the $\frac{\beta_1 + \beta_2 E_i}{\beta_1 + \beta_2 E_i} = -\frac{125 \log_{10}(2)}{\beta_1} + \frac{125 \log_{10}(2) \beta_2 E_i}{\beta_1^2}$

uality is the degree-one Taylor series about E_i = י
e
al $\frac{1}{\beta_1^2}$ + $O(E_i^2)$, #(3)
bout $E_i = 0$; this is the r
estimating the base-lin where the second equality is the degree-one Taylor series about $E_i = 0$; this is the reason we
466 center E_i in our pre-processing. Thus we are interested in estimating the base-line half-life
467 $g_1(\beta_1, \beta_3) = -0.25 \log$ 467 $g_1(\beta_1, \beta_3) = -0.25 \log_{10}(2) / \beta_1$ and the adjustment to half-life for every week delay in ART
468 $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$. Appealing the asymptotic normality of our parameter $g_1(\beta_1, \beta_3) = -0.25 \log_{10}(2) / \beta_1$ and the adjustment to half-life for every week delay in ART
 $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$. Appealing the asymptotic normality of our parameter

estimates and the multivariate $\frac{1}{2}$ stimates and the multivariate of half-life estimates: 468 $g_2(\beta_1,\beta_2)=0.25\log_{10}(2)$ β_2/β_1^2 . Appealing the asymptotic normality of our parameter 469 estimates and the multivariate delta method, we get the following asymptotic distribution for our 470 half-life estimates:

$$
\sqrt{n}\left(\begin{bmatrix} g_1(\widehat{\beta_1}, \widehat{\beta_2}) \\ g_2(\widehat{\beta_1}, \widehat{\beta_2}) \end{bmatrix} - \begin{bmatrix} g_1(\beta_1, \beta_2) \\ g_2(\beta_1, \beta_2) \end{bmatrix}\right) \stackrel{d}{\rightarrow} N\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, J \Sigma J^T\right) \#(4)
$$

$$
J = 0.25 \log_{10}(2) \begin{bmatrix} \frac{1}{\beta_1^2} & 0 \\ -2\frac{\beta_2}{\beta_1^2} & \frac{1}{\beta_1^2} \end{bmatrix} \#(5)
$$
where Σ is the covariance between β_1 and β_2 , and J is the Jacobian matrix

.
.
.ร l
n $-2\frac{72}{\beta_1^2}$ $\frac{72}{\beta_1^2}$
d *J* is the . ا ئ $^{\epsilon}$ e l
ia where Σ is the covariance between β_1 and β_2 , and *J* is the Jacobian matrix of $g(\beta_1, \beta_2)$. We plug-
472 in $\hat{\Sigma}$, along with $\widehat{\beta_1}$ and $\widehat{\beta_2}$ from our model to estimate the asymptotic confidence i 472 in Σ̂, along with $β_1$ and $β_2$ from our model to estimate the asymptotic confidence intervals for
473 base-line half-life and adjustment to half-life for delay in ART initiation. Percent decay per week 473 base-line half-life and adjustment to half-life for delay in ART initiation. Percent decay per week

-
- before τ is calculated using the transformation $h(\beta_1) = -100 (2^{\beta_1} 1)$; the negative sign
accounts for the directionality of the decay. These calculations are the same for estimates of the
after the half-life that 475 accounts for the directionality of the decay. These calculations are the same for estimates of the

476 half-life τ . The after τ after τ .

Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population. Medians with

interquartile ranges and frequencies with percentages are shown.

^a Median baseline plasma log_{10} HIV RNA = 2.2 copies/mL.

Figure 1. **Fitted models match observed HIV reservoir patterns for HIV intact and defective DNA**.

The decay patterns for each participant are shown as thin grey lines, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patters were observed for HIV intact (left panel) and total combined (3' plus 5') defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant predictions were made by taking the mean of E_i
(estimated time between HIV infection and ART initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀)
pre-ART pla (estimated time between HIV infection and ART initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀
pre-ART plasma viral load) across participants from our final model.
a. pre-ART plasma viral load) across participants from our final model.

a.

b.

Figure 2. An inflection point (τ = 5 **weeks) was chosen from a grid from 0 weeks to 24 weeks, by half-weeks**. Results are shown for both intact (a) and defective (b) HIV DNA decay models, respectively. The biphasic decay model's inflection point was tuned by estimating the τ that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper panels) and leave-oneout mean squared error (MSE, lower panels). The best τ for each loss (red point) is shown in relation to the final model's selected inflection point of $\tau = 5$ weeks as reference (vertical dashed line).

Figure 3. Lower pre-ART viral load and higher initial CD4+ T counts are associated with lower HIV DNA reservoirs in fitted spline models. Fitted spline models with corresponding 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against log_{10} pre-ART viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm³ was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial CD4+ T cell count of 300 cells/mm³. Similar patterns were observed for HIV defective DNA, but the fitted splines were less linear (b).

Figure 4. **Clinical factors influence HIV intact and defective DNA decay rates**. Faster decay rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and defective DNA, respectively. Individual participant decay rates shown in thin black lines, and cohort medians shown by bold black solid or dashed lines.

a.

b.

c.

1 **Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay**

2 **rates.** Average model predictions were made by bootstrapping 300 random participants and 3 predicting their HIV DNA counts, the model predictions were then averaged within each stratum 4 (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell 5 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that 6 slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir 7 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits 8 were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay 9 (weeks 5-24).

- 10
- 11 **a.**

b.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

23 **REFERENCES**

- 24 1 Chun, T. W. *et al.* Rebound of plasma viremia following cessation of antiretroviral
- 25 therapy despite profoundly low levels of HIV reservoir: implications for
- 26 eradication. *AIDS* **24**, 2803-2808 (2010).
- 27 https://doi.org:10.1097/QAD.0b013e328340a239
- 28 2 Hocqueloux, L. *et al.* Long-term immunovirologic control following antiretroviral
- 29 therapy interruption in patients treated at the time of primary HIV-1 infection.
- 30 *AIDS* **24**, 1598-1601 (2010). https://doi.org:10.1097/qad.0b013e32833b61ba
- 31 3 White, J. A. *et al.* Complex decay dynamics of HIV virions, intact and defective
- 32 proviruses, and 2LTR circles following initiation of antiretroviral therapy. *Proc Natl*
- 33 *Acad Sci U S A* **119** (2022). https://doi.org:10.1073/pnas.2120326119
- 34 4 Perelson, A. S. *et al.* Decay characteristics of HIV-1-infected compartments
- 35 during combination therapy. *Nature* **387**, 188-191 (1997).
- 36 https://doi.org:10.1038/387188a0
- 37 5 Kwon, K. J. & Siliciano, R. F. HIV persistence: clonal expansion of cells in the
- 38 latent reservoir. *J Clin Invest* **127**, 2536-2538 (2017).
- 39 https://doi.org:10.1172/JCI95329
- 40 6 Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. *Cell* **93**, 665-671
- 41 (1998). https://doi.org:10.1016/s0092-8674(00)81427-0
- 42 7 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival
- 43 and homeostatic proliferation. *Nature medicine* **15**, 893-900 (2009).
- 44 https://doi.org:10.1038/nm.1972

- 45 8 Yukl, S. A. *et al.* Differences in HIV burden and immune activation within the gut
- 46 of HIV-positive patients receiving suppressive antiretroviral therapy. *The Journal*
- 47 *of infectious diseases* **202**, 1553-1561 (2010). https://doi.org:10.1086/656722
- 48 9 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients
- 49 on antiretroviral therapy. *Nature* **487**, 482-485 (2012).
- 50 https://doi.org:10.1038/nature11286
- 51 10 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV
- 52 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 53 https://doi.org:10.1016/S2352-3018(15)00226-X
- 54 11 Rasmussen, T. A. *et al.* Panobinostat, a histone deacetylase inhibitor, for latent-
- 55 virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a
- 56 phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13-21 (2014).
- 57 https://doi.org:10.1016/S2352-3018(14)70014-1
- 58 12 Elliott, J. H. *et al.* Activation of HIV transcription with short-course vorinostat in
- 59 HIV-infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,
- 60 e1004473 (2014). https://doi.org:10.1371/journal.ppat.1004473
- 61 13 Gay, C. L. *et al.* Assessing the impact of AGS-004, a dendritic cell-based
- 62 immunotherapy, and vorinostat on persistent HIV-1 Infection. *Sci Rep* **10**, 5134
- 63 (2020). https://doi.org:10.1038/s41598-020-61878-3
- 64 14 Fidler, S. *et al.* Antiretroviral therapy alone versus antiretroviral therapy with a
- 65 kick and kill approach, on measures of the HIV reservoir in participants with
- 66 recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet* **395**,
- 67 888-898 (2020). https://doi.org:10.1016/S0140-6736(19)32990-3

- 68 15 Gutierrez, C. *et al.* Bryostatin-1 for latent virus reactivation in HIV-infected
- 69 patients on antiretroviral therapy. *AIDS* **30**, 1385-1392 (2016).
- 70 https://doi.org:10.1097/QAD.0000000000001064
- 71 16 Vibholm, L. *et al.* Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts
- 72 Innate Immunity and Plasma Viremia in Individuals With Human
- 73 Immunodeficiency Virus Infection. *Clin Infect Dis* **64**, 1686-1695 (2017).
- 74 https://doi.org:10.1093/cid/cix201
- 75 17 Riddler, S. A. *et al.* Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune
- 76 Activation in Virally Suppressed Adults Living With Human Immunodeficiency
- 77 Virus-1. *Clin Infect Dis* **72**, e815-e824 (2021).
- 78 https://doi.org:10.1093/cid/ciaa1534
- 79 18 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV
- 80 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 81 https://doi.org:10.1016/S2352-3018(15)00226-X
- 82 19 Bar, K. J. *et al.* Effect of HIV Antibody VRC01 on Viral Rebound after Treatment
- 83 Interruption. *N Engl J Med* **375**, 2037-2050 (2016).
- 84 https://doi.org:10.1056/NEJMoa1608243
- 85 20 Gunst, J. D. *et al.* Early intervention with 3BNC117 and romidepsin at
- 86 antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized
- 87 trial. *Nat Med* **28**, 2424-2435 (2022). https://doi.org:10.1038/s41591-022-02023-7
- 88 21 Gunst, J. D. *et al.* in *Conference on Retroviruses and Opportunistic Infections.*
- 89 22 Archin, N. M. *et al.* Immediate antiviral therapy appears to restrict resting CD4+
- 90 cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl*

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

91 *Acad Sci U S A* **109**, 9523-9528 (2012).

92 https://doi.org:10.1073/pnas.1120248109

- 93 23 Buzon, M. J. *et al.* Long-term antiretroviral treatment initiated at primary HIV-1
- 94 infection affects the size, composition, and decay kinetics of the reservoir of HIV-
- 95 1-infected CD4 T cells. *J Virol* **88**, 10056-10065 (2014).
- 96 https://doi.org:10.1128/JVI.01046-14
- 97 24 Chun, T. W. *et al.* Early establishment of a pool of latently infected, resting
- 98 CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**,
- 99 8869-8873 (1998). https://doi.org:10.1073/pnas.95.15.8869
- 100 25 Strain, M. C. *et al.* Effect of treatment, during primary infection, on establishment
- 101 and clearance of cellular reservoirs of HIV-1. *J Infect Dis* **191**, 1410-1418 (2005).
- 102 https://doi.org:10.1086/428777
- 103 26 Hocqueloux, L., Saez-Cirion, A. & Rouzioux, C. Immunovirologic control 24
- 104 months after interruption of antiretroviral therapy initiated close to HIV
- 105 seroconversion. *JAMA Intern Med* **173**, 475-476 (2013).

106 https://doi.org:10.1001/jamainternmed.2013.2176

- 107 27 Ananworanich, J. *et al.* Virological and immunological characteristics of HIV-
- 108 infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 109 28 Ananworanich, J. *et al.* Impact of multi-targeted antiretroviral treatment on gut T
- 110 cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* **7**,
- 111 e33948 (2012). https://doi.org:10.1371/journal.pone.0033948
- 112 29 Deleage, C. *et al.* Impact of early cART in the gut during acute HIV infection. *JCI*
- 113 *Insight* **1** (2016). https://doi.org:10.1172/jci.insight.87065

- 114 30 Takata, H. *et al.* Long-term antiretroviral therapy initiated in acute HIV infection
- 115 prevents residual dysfunction of HIV-specific CD8(+) T cells. *EBioMedicine* **84**,
- 116 104253 (2022). https://doi.org:10.1016/j.ebiom.2022.104253
- 117 31 Oxenius, A. *et al.* Early highly active antiretroviral therapy for acute HIV-1
- 118 infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc*
- 119 *Natl Acad Sci U S A* **97**, 3382-3387 (2000).
- 120 https://doi.org:10.1073/pnas.97.7.3382
- 121 32 Streeck, H. *et al.* Immunological and virological impact of highly active
- 122 antiretroviral therapy initiated during acute HIV-1 infection. *J Infect Dis* **194**, 734-
- 123 739 (2006). https://doi.org:10.1086/503811
- 124 33 Namazi, G. *et al.* The Control of HIV After Antiretroviral Medication Pause
- 125 (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. *J*
- 126 *Infect Dis* **218**, 1954-1963 (2018). https://doi.org:10.1093/infdis/jiy479
- 127 34 Peluso, M. J. *et al.* Differential decay of intact and defective proviral DNA in HIV-
- 128 1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5** (2020).
- 129 https://doi.org:10.1172/jci.insight.132997
- 130 35 Gandhi, R. T. *et al.* Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral
- 131 Therapy. *J Infect Dis* **223**, 225-233 (2021). https://doi.org:10.1093/infdis/jiaa532
- 132 36 Gandhi, R. T. *et al.* Varied Patterns of Decay of Intact Human Immunodeficiency
- 133 Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. *J Infect Dis*
- 134 **227**, 1376-1380 (2023). https://doi.org:10.1093/infdis/jiad039

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

- 135 37 Antar, A. A. *et al.* Longitudinal study reveals HIV-1-infected CD4+ T cell
- 136 dynamics during long-term antiretroviral therapy. *J Clin Invest* **130**, 3543-3559
- 137 (2020). https://doi.org:10.1172/JCI135953
- 138 38 Shi, L. *et al.* in *International AIDS Society Conference on HIV Science.*
- 139 39 Ananworanich, J. *et al.* HIV DNA Set Point is Rapidly Established in Acute HIV
- 140 Infection and Dramatically Reduced by Early ART. *EBioMedicine* **11**, 68-72
- 141 (2016). https://doi.org:10.1016/j.ebiom.2016.07.024
- 142 40 Crowell, T. A. *et al.* Virologic failure is uncommon after treatment initiation during
- 143 acute HIV infection. *AIDS* **30**, 1943-1950 (2016).
- 144 https://doi.org:10.1097/QAD.0000000000001148
- 145 41 Lee SA, H. T., Gandhi M, Coffey S, Harting H, Hoh R, Peluso MJ, Siegel D,
- 146 Crouch P, Scott H, Cohen SD, Sachdev D, Bacon O, Busch M, Pilcher C,
- 147 Buchbinder S, Havlir DV, Deeks SG. in *International AIDS Society Conference.*
- 148 42 Grebe, E. *et al.* Interpreting HIV diagnostic histories into infection time estimates:
- 149 analytical framework and online tool. *BMC Infect Dis* **19**, 894 (2019).
- 150 https://doi.org:10.1186/s12879-019-4543-9
- 151 43 Fiebig, E. W. *et al.* Dynamics of HIV viremia and antibody seroconversion in
- 152 plasma donors: implications for diagnosis and staging of primary HIV infection.
- 153 *AIDS* **17**, 1871-1879 (2003).
- 154 https://doi.org:10.1097/01.aids.0000076308.76477.b8
- 155 44 Keele, B. F. *et al.* Identification and characterization of transmitted and early
- 156 founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*
- 157 **105**, 7552-7557 (2008). https://doi.org:10.1073/pnas.0802203105

- 158 45 Prevention., C. f. D. C. a. HIV Surveillance Report.
- 159 http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022.
- 160 Accessed Nov 2, 2023., (2020).
- 161 46 Buchbinder, S. P. & Havlir, D. V. Getting to Zero San Francisco: A Collective
- 162 Impact Approach. *J Acquir Immune Defic Syndr* **82 Suppl 3**, S176-S182 (2019).
- 163 https://doi.org:10.1097/QAI.0000000000002200
- 164 47 Cohen, S. E. *et al.* Acquisition of tenofovir-susceptible, emtricitabine-resistant
- 165 HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
- 166 *Lancet HIV* (2018). https://doi.org:10.1016/S2352-3018(18)30288-1
- 167 48 McMyn, N. F. *et al.* The latent reservoir of inducible, infectious HIV-1 does not
- 168 decrease despite decades of antiretroviral therapy. *J Clin Invest* **133** (2023).
- 169 https://doi.org:10.1172/JCI171554
- 170 49 Whitney, J. B. *et al.* Rapid seeding of the viral reservoir prior to SIV viraemia in
- 171 rhesus monkeys. *Nature* **512**, 74-77 (2014). https://doi.org:10.1038/nature13594
- 172 50 Leyre, L. *et al.* Abundant HIV-infected cells in blood and tissues are rapidly
- 173 cleared upon ART initiation during acute HIV infection. *Sci Transl Med* **12** (2020).
- 174 https://doi.org:10.1126/scitranslmed.aav3491
- 175 51 Ananworanich, J. *et al.* Virological and immunological characteristics of HIV-
- 176 infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).
- 177 52 Deeks, S. G. *et al.* Research priorities for an HIV cure: International AIDS Society
- 178 Global Scientific Strategy 2021. *Nat Med* **27**, 2085-2098 (2021).
- 179 https://doi.org:10.1038/s41591-021-01590-5

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

- 180 53 Gay, C. L. *et al.* Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1
- 181 Infected Participants on Suppressive Antiretroviral Therapy. *J Infect Dis* **215**,
- 182 1725-1733 (2017). https://doi.org:10.1093/infdis/jix191
- 183 54 Gay, C. L. *et al.* Suspected Immune-Related Adverse Events With an Anti-PD-1
- 184 Inhibitor in Otherwise Healthy People With HIV. *J Acquir Immune Defic Syndr* **87**,
- 185 e234-e236 (2021). https://doi.org:10.1097/QAI.0000000000002716
- 186 55 Colston, E. *et al.* An open-label, multiple ascending dose study of the anti-CTLA-
- 187 4 antibody ipilimumab in viremic HIV patients. *PLoS One* **13**, e0198158 (2018).
- 188 https://doi.org:10.1371/journal.pone.0198158
- 189 56 Reeves, D. B. *et al.* Impact of misclassified defective proviruses on HIV reservoir
- 190 measurements. *Nat Commun* **14**, 4186 (2023). https://doi.org:10.1038/s41467-
- 191 023-39837-z
- 192 57 Reeves, D. B. *et al.* A majority of HIV persistence during antiretroviral therapy is
- 193 due to infected cell proliferation. *Nat Commun* **9**, 4811 (2018).
- 194 https://doi.org:10.1038/s41467-018-06843-5
- 195 58 Shan, L. *et al.* Transcriptional Reprogramming during Effector-to-Memory
- 196 Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection.
- 197 *Immunity* **47**, 766-775 e763 (2017). https://doi.org:10.1016/j.immuni.2017.09.014
- 198 59 Jain, V. *et al.* Antiretroviral therapy initiated within 6 months of HIV infection is
- 199 associated with lower T-cell activation and smaller HIV reservoir size. *J Infect Dis*
- 200 **208**, 1202-1211 (2013). https://doi.org:10.1093/infdis/jit311

- 223 67 Finzi, D. *et al.* Identification of a reservoir for HIV-1 in patients on highly active
- 224 antiretroviral therapy. *Science* **278**, 1295-1300 (1997).
- 225 https://doi.org:10.1126/science.278.5341.1295
- 226 68 Siliciano, J. D. *et al.* Long-term follow-up studies confirm the stability of the latent
- 227 reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine* **9**, 727-728 (2003).
- 228 https://doi.org:10.1038/nm880
- 229 69 Kumar, M. R. *et al.* Biphasic decay of intact SHIV genomes following initiation of
- 230 antiretroviral therapy complicates analysis of interventions targeting the reservoir.
- 231 *Proc Natl Acad Sci U S A* **120**, e2313209120 (2023).
- 232 https://doi.org:10.1073/pnas.2313209120
- 233 70 Martin, A. R. *et al.* Similar Frequency and Inducibility of Intact Human
- 234 Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. *J Infect Dis*
- 235 **224**, 258-268 (2021). https://doi.org:10.1093/infdis/jiaa736
- 236 71 Simonetti, F. R. *et al.* Intact proviral DNA assay analysis of large cohorts of
- 237 people with HIV provides a benchmark for the frequency and composition of
- 238 persistent proviral DNA. *Proc Natl Acad Sci U S A* **117**, 18692-18700 (2020).
- 239 https://doi.org:10.1073/pnas.2006816117
- 240 72 Bruner, K. M. *et al.* A quantitative approach for measuring the reservoir of latent
- 241 HIV-1 proviruses. *Nature* **566**, 120-125 (2019). https://doi.org:10.1038/s41586-
- 242 019-0898-8
- 243
- 244
- 245
- 246

247 **FIGURE LEGENDS**

248 **Table 1. Baseline Characteristics of the UCSF Treat Acute Study Population**. Medians with 249 interquartile ranges and frequencies with percentages are shown.

250

251 **Figure 1**. **Fitted models match observed HIV reservoir patterns for HIV intact and** 252 **defective DNA**. The decay patterns for each participant are shown as thin grey lines, while the 253 decay pattern for the model-predicted average participant is shown as the thick black lines. 254 Biphasic decay patters were observed for HIV intact (left panel) and total combined (3' plus 5') 255 defective (right panel) (a). For defective HIV DNA, the biphasic decay pattern was observed 256 more strongly for 5' but also seen with 3' defective DNA (b). Average predicted participant predictions were made by taking the mean of E_i (estimated time between HIV infection and ART
258 initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀ pre-ART plasma viral load) across
259 participants from o 258 initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀ pre-ART plasma viral load) across
259 participants from our final model.
260 259 participants from our final model.

260

261 **Figure 2. An inflection point (**τ = 5 **weeks) was chosen from a grid from 0 weeks to 24** 262 **weeks, by half-weeks**. Results are shown for both intact (a) and defective (b) HIV DNA decay 263 models, respectively. The biphasic decay model's inflection point was tuned by estimating the τ 264 that minimized prediction error measured by leave-one-out mean absolute error (MAE, upper 265 panels) and leave-one-out mean squared error (MSE, lower panels). The best τ for each loss 266 (red point) is shown in relation to the final model's selected inflection point of $\tau = 5$ weeks as 267 reference (vertical dashed line).

268

269 **Figure 3. Lower pre-ART viral load and higher initial CD4+ T counts are associated with** 270 **lower HIV DNA reservoirs in fitted spline models**. Fitted spline models with corresponding 271 95% confidence intervals for HIV intact (a) and defective (b) DNA plotted against log_{10} pre-ART

272 viral load (left panel) and initial CD4+ T cell count (right panel). The fitted spline models are 273 plotted in red with corresponding 95% confidence intervals denoted by blue dashed lines. Lower 274 intact HIV DNA reservoirs (a) were associated with lower pre-ART viral load and higher initial 275 CD4+ T counts. For example, a participant with an initial CD4+ T cell count of 900 cells/mm³ 276 was predicted to have ~10 times smaller HIV intact reservoir than a participant with an initial 277 $CD4+T$ cell count of 300 cells/mm³. Similar patterns were observed for HIV defective DNA, but 278 the fitted splines were less linear (b).

279

280 **Figure 4**. **Clinical factors influence HIV intact and defective DNA decay rates**. Faster decay 281 rates were observed among individuals with earlier ART initiation (a), higher CD4+ T cell count 282 (b), and lower pre-ART viral load (c). Left and right panels show decay rates for HIV intact and 283 defective DNA, respectively. Individual participant decay rates shown in thin black lines, and 284 cohort medians shown by bold black solid or dashed lines.

285

286 **Figure 5. Model predictions demonstrate the impact of clinical factors on HIV DNA decay** 287 **rates.** Average model predictions were made by bootstrapping 300 random participants and 288 predicting their HIV DNA counts, the model predictions were then averaged within each stratum 289 (tertiles of clinical predictors of HIV reservoir size: timing of ART initiation, initial CD4+ T cell 290 count, and pre-ART viral load). The strata for each key clinical parameter demonstrated that 291 slight changes in these clinical parameters (e.g., by tertiles) significantly influence reservoir 292 decay rates for both intact and defective DNA. Predicted reservoir size 95% confidence limits 293 were narrower for the first phase of decay (weeks 0-5) relative to the second phase of decay 294 (weeks 5-24).

295

296 **Supplementary Figure 1. The UCSF Treat Acute HIV cohort study participants**. A total of 297 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.03.27.24304867;](https://doi.org/10.1101/2024.03.27.24304867) this version posted March 28, 2024. The copyright holder for this preprint

298 date of detected HIV infection (EDDI) using the Infection Dating Tool (https://tools.incidence-299 estimation.org/idt/). The numbers of study participants by Fiebig stages (I-V) of HIV recency are 300 also shown (https://doi.org:10.1097/01.aids.0000076308.76477.b8). PrEP = Pre-exposure 301 prophylaxis with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

302

303 **Supplementary Figure 2. Calculation of estimated dates of detected HIV infection**. The 304 estimated dates of detected HIV infection (EDDI), along with a "confidence interval" for early 305 probable (EP-EDDI) and late probable (LP-EDDI) dates, were calculated using participants' 306 clinical test results as well as baseline study visit confirmatory assay results.

307

308 **Supplementary Figure 3. Fiebig and race/ethnicity distribution within the UCSF Treat** 309 **Acute HIV cohort.** The distribution of study participants in the UCSF Treat Acute HIV cohort, by 310 timing of ART initiation (a) and self-reported race/ethnicity (b). A total of 67 participants met 311 inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV 312 infection (EDDI) using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/). The 313 proportions of study participants by Fiebig stages (I-V) are also shown in (a).

314

315 **Supplementary Figure 4. HIV-1/2 test results for study participants.** The proportion of study 316 participants with either negative and/or indeterminate test results for HIV-1/2 p24 317 antigen/antibody assay (Architect) (a) and HIV-1/2 differentiation (Geenius) antibody assay (b) 318 at baseline study visit were consistent with rates with our San Francisco Department of Public 319 Health rates (27% and 28%, respectively).

320

321 **Supplementary Figure 5. Observed HIV intact and defective reservoir decays highlighting** 322 **participants reporting a history of PrEP use**. Most participants did not report PrEP overlap

323 near the time of HIV diagnosis (grey lines). A subset of participants reported PrEP overlap 324 within 10 days of HIV diagnosis; N=6 participants acquired HIV while already taking PrEP 325 (yellow lines) and N=8 participants were prescribed PrEP but were found to already have 326 acquired HIV (blue lines).

327

328 **Supplementary Figure 6. Semiparametric monophasic, biphasic, and triphasic** 329 **generalized additive model fit comparison suggest biphasic model has the most** 330 **parsimonious fit**. Infection points were selected by minimizing the leave-one-out prediction 331 mean absolute error (MAE) for each model and both HIV DNA assays. Tuning results for the 332 triphasic model show that the best model (emphasized in red) either has two knots near each 333 other or one knot near zero (a) suggesting that it is similar in shape to a biphasic model; leave-334 one-out prediction mean squared error (MSE) is proved for extra support. The Akaike 335 information criteria (AIC) value and 95% confidence interval was then used to compare 336 monophasic, biphasic, and triphasic models for both assays (b). AIC estimates and confidence 337 intervals were found by fitting models on 500 bootstrap resampled data sets. For both HIV intact 338 and defective DNA, the biphasic and triphasic models had relatively equivalent performance.

339

340 **Supplementary Figure 7. Modeling using the full first year of data suggests reservoir** 341 **decay trends continue past the first 24 weeks on ART.** 65.7% of the total study participants 342 continued in the study beyond 24 weeks**.** Observed HIV reservoir patterns are shown as thin 343 grey lines, while the decay pattern for the model-predicted average participant is shown as the 344 thick black lines (a). Average predicted participant predictions were made by taking the mean of E_i (estimated time between HIV infection and ART initiation), C_i (initial CD4+ T cell count), and
346 V_i (log₁₀ pre-ART plasma viral load) across participants. Model inflection point tuning is shown
347 for both i 346 V_i (log₁₀ pre-ART plasma viral load) across participants. Model inflection point tuning is shown
347 for both intact (left panels) and defective (right panels) HIV DNA decay models, respectively (b).
348 The bipha 347 for both intact (left panels) and defective (right panels) HIV DNA decay models, respectively (b). 348 The biphasic decay model's inflection point was tuned by estimating the τ that minimized

349 prediction error measured by leave-one-out mean absolute deviation (MAE, upper panels) and 350 leave-one-out mean squared error (MSE, lower panels). A grid of τ values from weeks 0 to 52, 351 by half-weeks, was considered as potential inflection points. The best τ for each loss (red point) 352 is shown in relation to the final model's selected inflection point of $\tau = 5$ weeks as reference 353 (vertical dashed line).

354

355 **Supplementary Figure 8. Inflection point sensitivity analyses demonstrate some** 356 **variability when excluding populations of potential outliers.** To test whether the final model 357 inflection point selection of $\tau = 5$ weeks was influenced by potential outlier data we performed τ 358 estimation on three clinically interesting sub-populations. Separate models were fit that 359 excluded (a) participants reporting prior PrEP use (<10 days overlap between last PrEP use and 360 estimated date of detected HIV infection), (b) participants with plasma viral load "blips" (defined 361 as a one-time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL 362 between weeks 0-24), and (c) participants with sudden increases in HIV intact DNA (defined as 363 >50% increase between two consecutive measurements of HIV intact DNA during weeks 0-24). 364 A regular grid of possible τ was used (0-26 weeks by half-week) and the leave-one-out cross- τ was used (0-26 weeks by half-week) and the leave-one-out cross-
absolute prediction error (MAE) was computed for each candidate τ .
best prediction error is denoted with a red point and our selected 365 validation (LOOCV) mean absolute prediction error (MAE) was computed for each candidate τ. 366 The model attaining the best prediction error is denoted with a red point and our selected 367 inflection point $(\tau = 5)$ is shown with a dashed vertical line. Refer to **Supplementary Table 2** to 368 get the sample size for each sensitivity analysis and to **Supplementary Figure 9** to see which 369 patients are excluded from each sensitivity analysis.

370

371 **Supplementary Figure 9. Model estimate sensitivity analyses demonstrated that results** 372 **were overall unchanged after excluding populations of potential outliers**. The final model 373 $(\tau = 5$ weeks) was fit on three clinically interesting sub-populations to assess if the influence of

374 potential outlier data. Separate models were fit that excluded (a) participants reporting prior 375 PrEP use (<10 days overlap between last PrEP use and estimated date of detected HIV 376 infection), (b) participants with plasma viral load "blips" (defined as a one-time viral load >1000 377 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c) 378 participants with sudden increases in HIV intact DNA (defined as >50% increase between two 379 consecutive measurements of HIV intact DNA during weeks 0-24). Models were fit using the 380 cohort data (grey lines), but not the potential outlier data (red lines). The resulting predict 381 average participant HIV reservoir decay patterns are shown as thick black lines. Refer to 382 **Supplementary Table 2** to get the sample sizes and half-life estimates for each sensitivity 383 analysis.

384

385 **Supplementary Figure 10. Predicted versus observed plots show good model** 386 **performance for both HIV intact and defective DNA**. Validation for the final models for intact 387 and defective HIV DNA decay was initially performed by looking at the plots of predicted vs 388 observed HIV DNA counts. These plots show that both models produce relatively unbiased 389 estimates across the observed range of HIV DNA counts and that the residual variance in the 390 defective reservoir is much higher than the intact reservoir. A dashed, red line at $y=x$ is added to 391 help interpret the model fits.

392

393 **Supplementary Table 1. Model estimates of HIV intact and defective DNA decay rates** 394 **from baseline models**. Baseline models include random intercepts for each participant but are 395 otherwise unadjusted for clinical covariates. Model estimates are provided for discrete periods 396 of ART suppression after initial treatment initiation: weeks 0 up to $\tau = 5$ and for weeks after τ .

397

398 **Supplementary Table 2. Model estimates of HIV intact and defective DNA decay rates** 399 **from models adjusted for initial CD4+ T cell count, pre-ART HIV RNA, and timing of ART**

403

404 **Supplementary Table 3. Changes in HIV decay rates of intact and defective DNA** 405 **associated with timing of ART initiation**. Faster decay rates in both intact and defective HIV 406 DNA during phase 1 are associated with lower delay in ART initiation. Intact, but not defective, 407 HIV DNA have faster predicted decay rates associated with lower delay in ART initiation.

408

409 **Supplementary Table 4. Changes in the intact and defective HIV DNA reservoir size** 410 **associated with initial CD4+ T cell count and pre-ART viral load**. Table values are log₁₀ 411 adjustments to the viral reservoir size at each clinical parameter. Higher initial CD4+ T cell count 412 and lower pre-ART viral load are associated with smaller viral reservoirs. Additional estimates 413 can be taken from **Figure 3**.